Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing continued drug innovation.

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

We are excited to be among the first companies to introduce a high-quality, affordable biosimilar Ustekinumab to this patient population." YESINTEK will have commercial payor coverage at launch ...

Patients who received the biosimilar in the first period continued to do so at week 52; those who received Prolia were randomly assigned to continue the treatment or switch to the biosimilar during ...

SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the medicine is commercially available to patients ...

SELARSDI is approved for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in patients aged 6 and older. Biosimilars like SELARSDI provide cost-saving ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...